Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease

Gene Therapy volume 11, pages 746–756 (2004)Cite this article

Abstract

A new adenoviral vector (Ad-GFAP-GDNF) (Ad=adenovirus, GFAP=glial fibrillary acidic protein, GDNF=glial cell line-derived neurotrophic factor) was constructed in which (i) the E1,E3/E4 regions of Ad5 were deleted and (ii) the GDNF transgene is driven by the GFAP promoter. We verified, in vitro, that the recombinant GDNF was expressed in primary cultures of astrocytes. In vivo, the Ad-GFAP-GDNF was injected into the striatum of rats 1 week before provoking striatal 6-OHDA lesion. After 1 month, the striatal GDNF levels were 37 pg/μg total protein. This quantity was at least 120-fold higher than in nontransduced striatum or after injection of the empty adenoviral vector. At 3 months after viral injection, GDNF expression decreased, whereas the viral DNA remained unchanged. Furthermore, around 70% of the dopaminergic (DA) neurons were protected from degeneration up to 3 months as compared to about 45% in the control groups. In addition, the amphetamine-induced rotational behavior was decreased. The results obtained in this study on DA neuron protection and rotational behavior are similar to those previously reported using vectors with viral promoters. In addition to these results, we established that a high level of GDNF was present in the striatum and that the period of GDNF expression was prolonged after injection of our adenoviral vector.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 9
Figure 8

Similar content being viewed by others

References

  1. Sauer H, Rosenblad C, Björklund A . Glial cell line-derived neurotrophic factor but not transforming growth factor-β prevents degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 1995; 92: 8935–8939.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rosenblad C, Martinez-Serrano A, Björklund A . Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induced recovery of function in a rat model of Parkinson's disease. Neuroscience 1998; 82: 128–137.

    Google Scholar 

  3. Rosenblad C et al. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricule. Eur J Neurosci 1999; 11: 1554–1566.

    Article  CAS  PubMed  Google Scholar 

  4. Rosenblad C, Kirik D, Björklund A . Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol 2000; 161: 503–516.

    Article  CAS  PubMed  Google Scholar 

  5. Kordower JH et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. New Engl J Med 1995; 332: 1118–1124.

    Article  CAS  PubMed  Google Scholar 

  6. Piccini P et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2: 1137–1140.

    Article  CAS  PubMed  Google Scholar 

  7. Freed CR et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New Engl J Med 2001; 344: 710–719.

    Article  CAS  PubMed  Google Scholar 

  8. Björklund A et al. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000; 886: 82–98.

    Article  PubMed  Google Scholar 

  9. Kirik D, Rosenblad C, Björklund A, Mandel RJ . Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosc 2000; 20: 4686–4700.

    Article  CAS  Google Scholar 

  10. Le Gal La Salle G et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988–990.

    Article  CAS  PubMed  Google Scholar 

  11. Bilang-Bleuel A et al. Intrastriatal injection of an adenoviral vector expressing glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc Natl Acad Sci USA 1997; 94: 8818–8823.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Choi-Lundberg DL et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838–841.

    Article  CAS  PubMed  Google Scholar 

  13. Sauer H, Oertel WH . Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde and immunocytochemical study in the rat. Neuroscience 1994; 59: 401–415.

    Article  CAS  PubMed  Google Scholar 

  14. Connor B et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged parkinsonian rat. Gene Therapy 1999; 6: 1936–1951.

    Article  CAS  PubMed  Google Scholar 

  15. Kozlowski DA et al. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp Neurol 2000; 166: 1–15.

    Article  CAS  PubMed  Google Scholar 

  16. Yeh P et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70: 559–565.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Dedieu JF et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71: 4626–4637.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Cui W et al. Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia 2001; 34: 272–282.

    Article  CAS  PubMed  Google Scholar 

  19. O'Malley EK, Sieber BA, Black IB, Dreyfus CF . Mesencephalic type I astrocytes mediate the survival of substantia nigra dopaminergic neurons in culture. Brain Res 1992; 582: 65–70.

    Article  CAS  PubMed  Google Scholar 

  20. Traugott U, Lebon P . Multiple Sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 1988; 24: 243–251.

    Article  CAS  PubMed  Google Scholar 

  21. Lindholm D et al. Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol 1992; 117: 395–400.

    Article  CAS  PubMed  Google Scholar 

  22. Nicole et al. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosc 2001; 21: 3024–3033.

    Article  CAS  Google Scholar 

  23. Mizuta I et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosc Lett 2001; 310: 117–120.

    Article  CAS  Google Scholar 

  24. Brenner M et al. GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 1994; 14: 1030–1037.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. McKie EA, Graham DI, Brown SM . Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector-potential glioblastoma targeting. Gene Therapy 1998; 5: 440–450.

    Article  CAS  PubMed  Google Scholar 

  26. Martin D et al. Glial cell line-derived neurotrophic factor: the lateral cerebral ventricule as a site of administration for stimulation of the subtantia nigra dopamine system in rats. Eur J Neurosci 1996; 8: 1249–1255.

    Article  CAS  PubMed  Google Scholar 

  27. Kirik D, Rosenblad C, Björklund A . Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998; 152: 259–277.

    Article  CAS  PubMed  Google Scholar 

  28. Bovolenta P, Liem RKH, Mason CA . Development of cerebella astroglia: transition in form and cytoskeletal content. Del Biol 1984; 102: 248–259.

    Article  CAS  Google Scholar 

  29. Morelli AE et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types and abolish peripheral liver toxicity. J Gen Virol 1999; 80: 571–583.

    Article  CAS  PubMed  Google Scholar 

  30. Byrnes AP, Rusby JE, Wood MJA, Charlton HM . Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66: 1015–1024.

    Article  CAS  PubMed  Google Scholar 

  31. Tripathy SK, Black HB, Golwasser E, Leiden JM . Immune responses to transgene-encoded protein limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545–550.

    Article  CAS  PubMed  Google Scholar 

  32. Choi-Lundberg DL et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 1998; 154: 261–275.

    Article  CAS  PubMed  Google Scholar 

  33. Armentano D et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71: 2408–2416.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Georgievska B, Kirik D, Björklund A . Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line-derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002; 177: 461–474.

    Article  CAS  PubMed  Google Scholar 

  35. Lee CS, Sauer H, Björklund A . Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996; 72: 641–653.

    Article  CAS  PubMed  Google Scholar 

  36. Crouzet J et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci USA 1997; 94: 1414–1419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kozak M . Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 1984; 12: 857–872.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lin LFH et al. GDNF, a glial cell line-derived neurotrophic factor for mid brain dopaminergic neurons. Science 1993; 260: 1130–1132.

    Article  CAS  PubMed  Google Scholar 

  39. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P . Widespread long-term gene transfer to mouse skeletal muscles and heart via an adenovirus vector. J Clin Invest 1992; 90: 626–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Blanche F et al. An improved anion-exchange HPLC methods for the detection and purification of adenoviral particles. Gene Therapy 2000; 7: 1055–1062.

    Article  CAS  PubMed  Google Scholar 

  41. Lundberg C, Horrelou P, Mallet J, Björklund A . Generation of Dopa-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp Neurol 1996; 139: 39–53.

    Article  CAS  PubMed  Google Scholar 

  42. Horellou P et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. NeuroReport 1994; 6: 49–53.

    Article  CAS  PubMed  Google Scholar 

  43. Bodeau-Pean S et al. A human tyrosine hydroxylase isoform associated with progressive supranuclear palsy shows altered enzymatic activity. J Biol Chem 1999; 274: 3469–3475.

    Article  CAS  PubMed  Google Scholar 

  44. Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–254.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Drs P Horellou and H Koenig for helpful discussions, Dr P Fender for viral stock preparation, Mr P Colin for surgery assistance and Mrs S Guyot for preparation of empty adenovirus. This work was supported by Centre National de la Recherche Scientifique, Pierre et Marie Curie University and IRME France.

Author information

Authors and Affiliations

  1. Laboratoire de Genetique Moleculaire de la Neurotransmission et des Processus Neurodegeneratifs, CNRS, Bat. CERVI, Hopital Pitie-Salpetriere, Paris, France

    N A Do Thi, P Saillour, J Mallet & T Paunio

  2. Gencell SAS, Vitry sur Seine, France

    L Ferrero & J F Dedieu

  3. Department of Molecular Medicine, Biomedicum, Helsinki, Finland

    T Paunio

Authors
  1. N A Do Thi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Saillour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Ferrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J F Dedieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Mallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Paunio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Do Thi, N., Saillour, P., Ferrero, L. et al. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther 11, 746–756 (2004). https://doi.org/10.1038/sj.gt.3302222

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302222

Keywords

This article is cited by

Search

Advanced search

Quick links